Researchers assessed the frequency and determinants of flares in patients with systemic lupus erythematosus, as well as studied the effects of glucocorticoid tapering on flares in patients who achieved low disease activity or remission.
Researchers studied the association between SLICC Frailty Index and damage accrual in patients with systemic lupus erythematosus.
For patients with systemic lupus erythematosus, iberdomide at a higher dose is superior to placebo for the rate of response indicating reduction in disease activity.
Researchers analyzed patient-reported outcomes by BICLA responses with anifrolumab or placebo in patients with moderate to severe SLE.
Researchers assessed the safety, pharmacokinetics, pharmacodynamics, and efficacy of iberdomide in patients with systemic lupus erythematosus.
Researchers assessed the efficacy of anifrolumab on organ domain-specific SLE disease activity.
The aim of the study was to determine the characteristics associated with severe COVID-19 outcomes among patients with systemic lupus erythematosus
Researchers studied the association between antinuclear antibody titer and specificity, as well as between the number of positive autoantibodies in antinuclear antibodies and specificity in systemic lupus erythematosus.
Researchers studied the associations between antinuclear antibody, complement, and interferon gene signature in the pathogenesis of systemic lupus erythematosus.
Researchers studied the role of serum IFN-α levels and IFN-I gene score in assessing disease activity in systemic lupus erythematosus.
